Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 22;11(5):e006649. doi: 10.1136/jitc-2022-006649

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CRISPRa-engineered IL-15-secreting NK cells slow down progression of MYC-overexpressing B-ALL in vivo. (A)Experimental design for comparing the in vivo therapeutic efficacies of CRISPRa-engineered IL-15 producing and control NK cells in a luciferase-labeled human cell line-derived xenograft (CDX) of MYC-driven B-cell malignancy (P493-6). Schematic was created using BioRender.com. (B)Bioluminescence imaging of leukemia progression in NOD-SCID IL2Rγ ^−/− (NSG) CDX recipients before (day 9 post-CDX transplantation) and after treatment with control and IL-15 NK cells (days 12 and 15 post-CDX transplantation) (n=6 mice each in control NK and IL-15 NK arms). (C)Quantification of fold change in full body bioluminescence (photons/sec/cm²/sr) on days 12 and 15 post B-lymphoblast transplantation in control-NK (n=6) and IL-15-NK- treated (n=6) CDX recipients. P values were calculated by Mann-Whitney U test. Exact significant p values (<0.05) are provided. B-ALL, B-cell acute lymphoblastic leukemia; NK, natural killer.